Nicolas E C, Scholz T H
The DuPont Merck Pharmaceutical Company, Deepwater, NJ 08023, USA.
J Pharm Biomed Anal. 1998 Jan;16(5):813-24. doi: 10.1016/s0731-7085(97)00131-3.
Monitoring of drug substance impurities is routinely accomplished using HPLC. However, HPLC retention times can vary, resulting in uncertainty as to whether a peak at a new retention time is a new impurity. Because standards of the minor impurities (less than 0.1% by area) are not usually available, some method is needed to characterize each of these peaks without isolating them. This on-line characterization might be accomplished using UV diode array spectral matching. This work sought to assess the sensitivity and selectivity of UV spectral matching for monitoring the impurity profile of drugs, using as an illustration DuP 941, an anti-cancer drug under development. An ultraviolet spectral data library was generated for a number of the DuP 941 impurities in the earliest safety lot. Impurities in several subsequent lots of DuP 941 were then examined to see how well their spectral characteristics matched those of the spectra contained in the library. We found LC/UV spectral matching to be a powerful method to monitor Dup 941 impurities even down to levels well below 0.1% by area. Critical factors that were shown to influence the utility of the technique include detector sensitivity, lamp intensity, and the presence of other impurities with very similar UV spectra.
原料药杂质的监测通常采用高效液相色谱法(HPLC)来完成。然而,HPLC的保留时间可能会有所不同,这就导致对于新保留时间处出现的峰是否为新杂质存在不确定性。由于通常无法获得次要杂质(面积小于0.1%)的标准品,因此需要某种方法来对这些峰进行表征而无需将它们分离出来。这种在线表征可以通过紫外二极管阵列光谱匹配来实现。这项工作旨在评估紫外光谱匹配用于监测药物杂质谱的灵敏度和选择性,以正在研发的抗癌药物DuP 941为例进行说明。针对最早安全批次中DuP 941的多种杂质建立了一个紫外光谱数据库。随后对DuP 941后续多个批次中的杂质进行检测,以考察其光谱特征与数据库中光谱的匹配程度。我们发现液相色谱/紫外光谱匹配是监测DuP 941杂质的一种有效方法,甚至对于面积远低于0.1%的杂质也能检测到。已证明影响该技术实用性的关键因素包括检测器灵敏度、灯强度以及具有非常相似紫外光谱的其他杂质的存在。